Jelinek G A, Will R, Dusci L J, Potter J M, Black K A
Department of Emergency Medicine, Fremantle Hospital, WA, Australia.
Rheumatol Int. 1991;11(4-5):147-50. doi: 10.1007/BF00332552.
Intravenous regional administration of corticosteroid (IVRAS) in the treatment of rheumatoid arthritis of the hand has not been reported previously. The method is based on a modification of Bier's block, with substitution of corticosteroid for local anaesthetic. Twenty-two patients were assessed in this double-blind, placebo-controlled study. The technique was safe and effective in improving grip strength, with a group mean improvement of more than 50%. Because suppression of endogenous cortisol production 24 h after treatment was commensurate with the dose of methylprednisolone used (40 mg), we could not exclude that the response may have been due to systemic steroid. Further studies are required to define the real value of IVRAS as it may offer alternative treatment of the joints and tendons within the hand and wrist in some patients rather than more prolonged oral therapy or individual, multiple joint or sheath injections.
此前尚未有关于静脉区域注射皮质类固醇(IVRAS)治疗手部类风湿性关节炎的报道。该方法基于对比尔氏阻滞的改良,用皮质类固醇替代局部麻醉剂。在这项双盲、安慰剂对照研究中对22名患者进行了评估。该技术在提高握力方面安全有效,组平均改善率超过50%。由于治疗后24小时内内源性皮质醇生成的抑制与所用甲泼尼龙的剂量(40毫克)相当,我们不能排除这种反应可能是由于全身性类固醇所致。需要进一步研究来确定IVRAS的实际价值,因为它可能为一些患者提供手部和腕部关节及肌腱的替代治疗,而非更长时间的口服治疗或单独的多关节或腱鞘注射。